Loading Valuation Snapshot...
Stock DNA
Pharmaceuticals & Biotechnology
INR 9,338 Cr ()
46.00
31
0.00%
0.00
0.00%
15.62
Revenue and Profits:
Net Sales:
342 Cr
(Quarterly Results - Dec 2025)
Net Profit:
41 Cr
Total Returns (Price + Dividend) 
Dividend Yield (0%)
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
3.75%
0%
3.75%
6 Months
0%
0%
0.0%
1 Year
0%
0%
0.0%
2 Years
0%
0%
0.0%
3 Years
0%
0%
0.0%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%
Corona Remedies for the last several years.
Risk Adjusted Returns v/s 
Returns Beta
Beta has not been calculated since enough price history is not available
News
No Recent News for the Company
Announcements 
Closure of Trading Window
30-Mar-2026 | Source : BSEIntimation of Closure of Trading Window
Announcement under Regulation 30 (LODR)-Press Release / Media Release
30-Mar-2026 | Source : BSEPress Release titled CORONA Remedies announces strategic acquisition of Wokadine in India
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
27-Feb-2026 | Source : BSEIntimation of Schedule of Analyst / Investor Meeting
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
0
EBIT to Interest (avg)
19.13
Debt to EBITDA (avg)
0.38
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
1.86
Tax Ratio
24.78%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
8.60%
ROCE (avg)
29.97%
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
46
Industry P/E
31
Price to Book Value
15.15
EV to EBIT
45.20
EV to EBITDA
38.20
EV to Capital Employed
15.30
EV to Sales
7.66
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
33.85%
ROE (Latest)
24.61%
Technicals key factors
Indicator
Weekly
Monthly
MACD
RSI
No Signal
Bollinger Bands
KST
Dow Theory
Mildly Bearish
OBV
Bullish
Shareholding Snapshot : Dec 2025
Shareholding Compare (%holding) 
Majority shareholders
Promoters
Pledged Promoter Holdings
None
Mutual Funds
Held by 13 Schemes (6.38%)
FIIs
Held by 18 FIIs (1.84%)
Promoter with highest holding
Ankurbhai K Mehta (22.0%)
Highest Public shareholder
Sepia Investments Limited (19.76%)
Individual Investors Holdings
1.36%
Quarterly Results Snapshot (Standalone) - Dec'25 - QoQ
Dec'25
Sep'25
Change(%)
Net Sales
342.42
361.13
-5.18%
Operating Profit (PBDIT) excl Other Income
83.16
78.47
5.98%
Interest
1.66
1.93
-13.99%
Exceptional Items
-19.10
0.00
Standalone Net Profit
41.25
52.15
-20.90%
Operating Profit Margin (Excl OI)
24.29%
21.73%
2.56%
Values in Rs Cr.
Net Sales
QoQ Growth in quarter ended Dec 2025 is -5.18% vs 4.21% in Sep 2025
Standalone Net Profit
QoQ Growth in quarter ended Dec 2025 is -20.90% vs 12.39% in Sep 2025
Annual Results Snapshot (Standalone) - Mar'25
Mar'25
Change(%)
Net Sales
1,196.42
NA
NA
Operating Profit (PBDIT) excl Other Income
239.98
NA
NA
Interest
10.60
NA
NA
Exceptional Items
0.00
NA
NA
Standalone Net Profit
149.05
NA
NA
Operating Profit Margin (Excl OI)
20.06%
NA%
NA
Values in Rs Cr.
Net Sales
Not Applicable: The company has declared_date for only one period
Standalone Net Profit
Not Applicable: The company has declared_date for only one period